

ASX RELEASE

10 November 2021

## KAZIA ANNUAL GENERAL MEETING RESULTS

Sydney, 10 November 2021 – Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce the results of its Annual General Meeting of shareholders.

All resolutions were carried. The vote totals are attached.

[ENDS]

### About Kazia Therapeutics Limited

Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) is an oncology-focused drug development company, based in Sydney, Australia.

Our lead program is paxalisib, a brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat glioblastoma, the most common and most aggressive form of primary brain cancer in adults. Licensed from Genentech in late 2016, paxalisib commenced recruitment to GBM AGILE, a pivotal study in glioblastoma, in January 2021. Eight additional studies are active in various forms of brain cancer. Paxalisib was granted Orphan Drug Designation for glioblastoma by the US FDA in February 2018, and Fast Track Designation for glioblastoma by the US FDA in August 2020. In addition, paxalisib was granted Rare Pediatric Disease Designation and Orphan Designation by the US FDA for DIPG in August 2020.

Kazia is also developing EVT801, a small-molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical data has shown EVT801 to be active against a broad range of tumour types and has provided compelling evidence of synergy with immuno-oncology agents. A phase I study commenced recruitment in November 2021.

For more information, please visit [www.kaziatherapeutics.com](http://www.kaziatherapeutics.com) or follow us on Twitter @KaziaTx.

This document was authorized for release to the ASX by James Garner, Chief Executive Officer, Managing Director.

### Board of Directors

**Mr Iain Ross** Chairman, Non-Executive Director

**Mr Bryce Carmine** Non-Executive Director

**Mr Steven Coffey** Non-Executive Director

**Dr James Garner** Chief Executive Officer, Managing Director

**KAZIA THERAPEUTICS LIMITED**  
**2021 Annual General Meeting**  
**Wednesday, 10 November 2021**  
**Results of Meeting**

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried
1 Adoption of Remuneration Report	Ordinary	49,207,558 92.29%	3,878,538 7.27%	235,430 0.44%	577,684	49,828,789 92.78%	3,878,538 7.22%	577,684	Carried
2 Re-Election of Iain Ross	Ordinary	54,570,330 97.05%	1,386,017 2.47%	267,430 0.48%	62,545	55,223,561 97.55%	1,386,017 2.45%	62,545	Carried
3 Adoption of Employee Share Option Plan	Ordinary	48,959,855 91.47%	4,330,036 8.09%	235,430 0.44%	1,825,140	49,581,086 91.97%	4,330,036 8.03%	1,825,140	Carried
4 Grant of up to 1,000,000 FY20 option to Dr James Garner	Ordinary	48,084,146 89.84%	5,198,416 9.72%	236,480 0.44%	830,168	48,706,427 90.36%	5,198,416 9.64%	830,168	Carried
5 Grant of up to 1,500,000 FY20 option to Dr James Garner	Ordinary	48,840,011 91.26%	4,440,721 8.30%	235,430 0.44%	833,048	49,461,242 91.76%	4,440,721 8.24%	833,048	Carried
6 Ratification of prior issue of Placement Shares	Ordinary	53,576,061 95.74%	2,137,610 3.82%	247,430 0.44%	325,221	54,134,292 96.20%	2,137,610 3.80%	400,221	Carried
7 Approval of Additional Placement capacity under Listing Rule 7.1A	Special	51,779,004 92.82%	3,733,280 6.70%	267,434 0.48%	506,604	52,432,239 93.35%	3,733,280 6.65%	506,604	Carried

\* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.